The Side Effect Profile of Trazodone in Comparison to an Active Control and Placebo

Newton, Roger E.

doi:10.1097/00004714-198111001-00016

Cited by 37 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trazodone 100 mg had no effect on these morning measures in dysthymia, while in major depression we observed a significant improvement of numerical memory [43]. No deterioration in cognitive functions was observed in normal geriatric subjects when assessed 4 h after acute administration of 100 mg trazodone [58], while Newton [59] observed poor memory, difficulties in concentrating and loss of interest with continuous use of trazodone.…”

Section: Discussionmentioning

confidence: 50%

Insomnia Related to Dysthymia: Polysomnographic and Psychometric Comparison with Normal Controls and Acute Therapeutic Trials with Trazodone

et al. 2001

View full text Add to dashboard Cite

Utilizing polysomnography (PSG) and psychometry, objective and subjective sleep and awakening quality was investigated in 11 patients (mean age 50 ± 14) with nonorganic insomnia (F 51.0) related to dysthymia (F 34.1) as compared with 11 age- and sex-matched normal controls. Patients demonstrated decreased sleep efficiency and sleep stage S2 as well as increased sleep latency to S1, S2 and S3, wakefulness within the total sleep period, number of awakenings, S1 and REM sleep. There was no intergroup difference in REM latency. Subjective sleep quality and the total score of the Self-Assessment Scale for Sleep and Awakening Quality (SSA) were deteriorated as were evening and morning well-being, mood, affectivity and drowsiness. Noopsychic measures showed deteriorated numerical memory, fine motor activity and reaction time variability. In a placebo-controlled crossover design study, the acute effects of 100 mg trazodone¹, a serotonin reuptake inhibitor with a sedative action due to 5HT₂ and α₁ receptor blockade, were investigated in the patients. As compared with placebo, trazodone induced an increase in slow-wave sleep (S3 + 4), a lengthening of REM latency, a decrease in REM sleep and a normalization of the periodic leg movement (PLM) index. In the morning, there was a minimal increase in somatic complaints and a decrease in critical flicker frequency and systolic blood pressure. In conclusion, our study demonstrated that dysthymia induced significant changes in objective and subjective sleep and awakening quality, which were counteracted by 100 mg trazodone, thus suggesting a key-lock principle in the treatment of nonorganic insomnia related to dysthymia with this drug.

show abstract

Section: Discussionmentioning

confidence: 50%

Insomnia Related to Dysthymia: Polysomnographic and Psychometric Comparison with Normal Controls and Acute Therapeutic Trials with Trazodone

et al. 2001

View full text Add to dashboard Cite

show abstract

“…In a side-effect profile study by Newton et al [27] of approximately 700 patients receiv ing buspirone, sedation, lethargy, and depres sion were comparable to placebo and were significantly less than with diazepam or clo razepate.…”

Section: Azaspirodecanedionesmentioning

confidence: 94%

Benzodiazepine and Nonbenzodiazepine Anxiolytics

Goldberg¹

1984

Psychopathology

View full text Add to dashboard Cite

A review of anxiolytic drugs is presented, including ethyl alcohol, barbiturates, diphenylmethane derivatives, glycerol and propanediol derivatives, antipsychotics, and anti-depressants. Focus on the benzodiazepines and their metabolism and method of action follows. The newest two groups are then reviewed: triazolobenzodiazepines and azaspirodecanediones. The first member of this latter group, buspirone, is then reviewed in detail including the author’s personal studies of the drug. The fact that it appears nonaddicting, nonsynergistic with alcohol, lacks impairment of driving-related skills, and is very effective in treating anxiety, may represent a breakthrough.

show abstract

“…Even when single doses of buspirone as high as 40 mg were used, the drug was less sedating than even the usual hypnotic dose of the barbituratc-likc drug, methaqualude [32], Clinical trials in anxious patients support these general conclusions. While approxi mately one third of patients on placebo re port apparent side effects, about 45% of pa tients on buspirone (at an average dose of 20 mg), and an average o f45-60% of patients on BZs [28,35], experience side effects. Con sidering only patients with moderate to se vere side effects, one study revealed these problems occurred in 33% of patients on buspirone and 69% of patients on diazepam [30],…”

Section: Side Effect and Safety Profilementioning

confidence: 99%

Clinical Studies of Buspirone

Schuckit¹

1984

Psychopathology

View full text Add to dashboard Cite

This literature review addresses two related questions: Is buspirone as clinically effective an antianxiety agent as the benzodiazepines ? And does buspirone offer any safety advantages? Data from over 1,000 anxious outpatients reveal that an average dose of 20 mg of buspirone/day appears to be as effective an antianxiety agent as comparable doses of diazepam or clorazepate in both acute and more chronic administration studies. Buspirone appears to cause less clinically significant impairment in cognition or motor performance, is less likely to potentiate the effects of brain depressants like alcohol, has little if any abuse liability, and produces no clinically identifiable physical abstinence syndrome when discontinued after long-term administration. While the final answer on the clinical usefulness and side effect profile of this interesting drug awaits the results of its use in divergent clinical settings, this new antianxiety agent appears to be equally effective in treating anxiety but is safer than the benzodiazepines.

show abstract

The Side Effect Profile of Trazodone in Comparison to an Active Control and Placebo

Cited by 37 publications

References 0 publications

Insomnia Related to Dysthymia: Polysomnographic and Psychometric Comparison with Normal Controls and Acute Therapeutic Trials with Trazodone

Insomnia Related to Dysthymia: Polysomnographic and Psychometric Comparison with Normal Controls and Acute Therapeutic Trials with Trazodone

Benzodiazepine and Nonbenzodiazepine Anxiolytics

Clinical Studies of Buspirone

Contact Info

Product

Resources

About